Inteum Company
Links
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - cancer%2foncology
85
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Small Molecule Inhibitors of Pleckstrin-2 for Treating Myeloproliferative Neoplasms
SHORT DESCRIPTION Small molecule inhibitors of Pleckstrin-2 (Plek2) for treating cell proliferative diseases and disorders, particularly myeloproliferative neoplasms (MPNs). NU Tech IDs: NU 2018-169, NU 2021-005 PRINCIPAL INVESTIGATOR Peng Ji Northwestern University Feinberg School of Medicine, Department of Pathology IP...
Published: 4/16/2026
|
Updated: 4/16/2026
|
Inventor(s):
Keywords(s):
Breast cancer
,
Cancer/Oncology
,
Colon cancer
,
Leukemia
,
Lung cancer
,
Pancreatic cancer
,
Small molecule
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Nano-therapeutics Targeting Cholesterol Efflux Transporter in Macrophages for Cancer Immunotherapy
NU 2025-160 INVENTORS Jason Miska* Feinberg School of Medicine, Department of Neurological Surgery Peng Zhang* Feinberg School of Medicine, Department of Neurological Surgery SHORT DESCRIPTION Novel nanoparticle technology that modulates macrophage cholesterol metabolism to boost anti-tumor immunity in GBM. BACKGROUND Glioblastoma...
Published: 4/16/2026
|
Updated: 4/14/2026
|
Inventor(s):
Keywords(s):
Adjunct therapy
,
Brain cancer
,
Cancer/Oncology
,
CNS - Central Nervous System
,
Drug delivery
,
Immunotherapy
,
Nanoparticle
,
Neurologic disease
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
SEC61 Complex as a Novel Therapeutic Target to Enhance Immunotherapy Response in Glioblastoma
NU 2023-011 INVENTORS Irina Balyasnikova* Northwestern University Feinberg School of Medicine, Department of Neurological Surgery Joseph Duffy SHORT DESCRIPTION A targeted therapeutic approach that inhibits the SEC61 complex to enhance responses to immunotherapy in glioblastoma. BACKGROUND Glioblastoma (GBM) is the most aggressive primary...
Published: 4/14/2026
|
Updated: 4/14/2026
|
Inventor(s):
Keywords(s):
Brain cancer
,
Cancer/Oncology
,
Immunotherapy
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Anti-TYRP1 Bi-specific T cell Engager for Treatment of TYRP1-expressing melanoma
NU 2022-123 INVENTORS Irina Balyasnikova (Feinberg School of Medicine, Department of Neurological Surgery)* Isabelle Le Poole (Feinberg School of Medicine, Department of Dermatology)* SHORT DESCRIPTION A bispecific T cell engager that targets CD3+ T cells and TYRP1-expressing melanoma cells. BACKGROUND Melanoma is the deadliest form of skin...
Published: 4/14/2026
|
Updated: 4/14/2026
|
Inventor(s):
Keywords(s):
Biologic
,
Cancer/Oncology
,
Immunotherapy
,
Melanoma
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Bi-specific Lipid Nanoparticles for Boosting Antitumor Immunity in Glioblastoma
NU 2022-151 SHORT DESCRIPTION A bispecific lipid nanoparticle that bridges tumor-associated myeloid cells (TAMCs) and glioma cells by dual checkpoint blockade and simultaneously reprograms TAMCs into antitumor effectors via targeted delivery of a STING agonist. INVENTORS Maciej Lesniak* Northwestern University Feinberg...
Published: 4/14/2026
|
Updated: 4/14/2026
|
Inventor(s):
Keywords(s):
Brain cancer
,
Cancer/Oncology
,
Drug delivery
,
Immunotherapy
,
Nanoparticle
,
Nanotechnology
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and neurodegenerative disorders
NU 2025-113 (NU 2016-137, NU 2018-176, NU 2019-179, NU 2023-007, NU 2024-250, NU 2025-038) INVENTORS Richard Silverman (Weinberg College of Arts and Sciences, Department of Chemistry) SHORT DESCRIPTION Novel highly selective neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and other cancers with high expression...
Published: 4/14/2026
|
Updated: 4/1/2026
|
Inventor(s):
Keywords(s):
ALS - Amyotrophic Lateral Sclerosis
,
AUTM26C1
,
BIAUTM1
,
Cancer/Oncology
,
Cardiology and Cardiovascular disease
,
Immunodeficiency
,
Immunology
,
Immunotherapy
,
Melanoma
,
Neurodegenerative disease
,
Neuroinflammation
,
nNOS
,
Small molecule
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Targeting EGFR Co-Amplified Long-Noncoding RNA for Glioblastoma Treatment
NU 2025-335 INVENTORS Shi-Yuan Cheng* Xiaozhou Yu Bo Hu Runxin Wu Xiao Song SHORT DESCRIPTION This invention provides compositions and methods for inhibiting ELDR and HELDR, two long non-coding RNAs (lncRNAs) that are frequently co-amplified in glioblastoma (GBM) with the epidermal growth factor receptor (EGFR) gene, and which drive tumorigenesis...
Published: 3/30/2026
|
Updated: 3/30/2026
|
Inventor(s):
Keywords(s):
Brain cancer
,
Cancer Treatment
,
Cancer/Oncology
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Targeted pH Sensitive Liposomes
NU 2020-170 INVENTORS Leo Gordon* Dong-Hyun Kim* Shuo Yang Wooram Park Taehoon Sim SHORT DESCRIPTION Liposomal nanoparticles composed of pH-sensitive lipids and apolipoprotein that encapsulate andrographolide for lymphoma treatment. BACKGROUND Lymphoma, particularly diffuse large B-cell lymphoma (DLBCL), is the most common aggressive type...
Published: 3/11/2026
|
Updated: 3/11/2026
|
Inventor(s):
Keywords(s):
Blood & Lymphatic disease
,
Cancer/Oncology
,
Nanoparticle
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Aminopyrimidine-based Kinase Inhibitors for Treatment of Cancer
NU 2015-098 Inventors Leonidas C. Platanias* Gary E. Schiltz Rama K. Mishra Short Description A small molecule to treat glioblastoma multiforme by blocking the Mnk pathway. Background Glioblastoma multiforme (GBM) is an aggressive brain cancer associated with a low survival rate, high recurrence, and limited therapeutic options. Most diagnosed...
Published: 3/5/2026
|
Updated: 3/5/2026
|
Inventor(s):
Keywords(s):
AD - Alzheimer’s Disease
,
Cancer/Oncology
,
Small molecule
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Covalent PRC2 Inhibitors for Advanced Cancer Therapeutics
SHORT DESCRIPTION Covalent inhibitors and proteolysis-targeting chimera (PROTAC) degraders targeting components of the PRC2 complex (EZH and EED) to block both enzymatic and non-enzymatic functions, offering robust anti-tumor efficacy. INVENTORS Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)* Jindan...
Published: 4/14/2026
|
Updated: 3/5/2026
|
Inventor(s):
Keywords(s):
AUTM26C1
,
BIAUTM1
,
Bladder cancer
,
Breast cancer
,
Cancer/Oncology
,
Covalent inhibitor
,
Lymphoma
,
Melanoma
,
PreSeed/Seed
,
Prostate cancer
,
PROTAC
,
Small molecule
,
Targeted protein degradation
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
1
2
3
4
5
6
7
8
9